320 related articles for article (PubMed ID: 21462307)
41. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.
Cullinane C; Dorow DS; Kansara M; Conus N; Binns D; Hicks RJ; Ashman LK; McArthur GA; Thomas DM
Cancer Res; 2005 Nov; 65(21):9633-6. PubMed ID: 16266981
[TBL] [Abstract][Full Text] [Related]
42. SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.
Li S; Zhao S; Liang N; Zhang S; Zhang L; Zhou L; Liu A; Cao X; Tian J; Yu Y; Fan Z; Xiao K; Wang M; Zhao H; Bai R; Sun J
Gastric Cancer; 2023 Sep; 26(5):677-690. PubMed ID: 37222910
[TBL] [Abstract][Full Text] [Related]
43. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
Wang WL; Conley A; Reynoso D; Nolden L; Lazar AJ; George S; Trent JC
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S15-24. PubMed ID: 21181476
[TBL] [Abstract][Full Text] [Related]
44. Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
Roberts KG; Odell AF; Byrnes EM; Baleato RM; Griffith R; Lyons AB; Ashman LK
Mol Cancer Ther; 2007 Mar; 6(3):1159-66. PubMed ID: 17363509
[TBL] [Abstract][Full Text] [Related]
45. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
Zhao J; Quan H; Xu Y; Kong X; Jin L; Lou L
Cancer Sci; 2014 Jan; 105(1):117-25. PubMed ID: 24205792
[TBL] [Abstract][Full Text] [Related]
46. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
[TBL] [Abstract][Full Text] [Related]
47. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13.
Bachet JB; Landi B; Laurent-Puig P; Italiano A; Le Cesne A; Lévy P; Safar V; Duffaud F; Blay JY; Emile JF
Eur J Cancer; 2013 Jul; 49(11):2531-41. PubMed ID: 23648119
[TBL] [Abstract][Full Text] [Related]
48. DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors.
Liu A; Zhang S; Wang M; Zhang L; Xu S; Nasimian A; Li S; Zhao S; Cao X; Tian J; Yu Y; Fan Z; Xiao K; Zhao H; Kazi JU; Ma L; Sun J
Mol Carcinog; 2024 Jan; 63(1):75-93. PubMed ID: 37737519
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
Tarn C; Skorobogatko YV; Taguchi T; Eisenberg B; von Mehren M; Godwin AK
Cancer Res; 2006 May; 66(10):5477-86. PubMed ID: 16707477
[TBL] [Abstract][Full Text] [Related]
50. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
[TBL] [Abstract][Full Text] [Related]
51. [Clinical and molecular characterization of gastrointestinal stromal tumors (GIST)].
Mac K; Wójcik M
Postepy Hig Med Dosw (Online); 2007 Jun; 62():272-81. PubMed ID: 18542042
[TBL] [Abstract][Full Text] [Related]
52. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
[TBL] [Abstract][Full Text] [Related]
53. ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours.
Gromova P; Rubin BP; Thys A; Cullus P; Erneux C; Vanderwinden JM
J Cell Mol Med; 2012 Feb; 16(2):306-17. PubMed ID: 21435173
[TBL] [Abstract][Full Text] [Related]
54. Familial gastrointestinal stromal tumor syndrome: report of 2 cases with KIT exon 11 mutation.
Jones DH; Caracciolo JT; Hodul PJ; Strosberg JR; Coppola D; Bui MM
Cancer Control; 2015 Jan; 22(1):102-8. PubMed ID: 25504284
[TBL] [Abstract][Full Text] [Related]
55. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.
Kleinbaum EP; Lazar AJ; Tamborini E; Mcauliffe JC; Sylvestre PB; Sunnenberg TD; Strong L; Chen LL; Choi H; Benjamin RS; Zhang W; Trent JC
Int J Cancer; 2008 Feb; 122(3):711-8. PubMed ID: 17943734
[TBL] [Abstract][Full Text] [Related]
56. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography.
Prenen H; Deroose C; Vermaelen P; Sciot R; Debiec-Rychter M; Stroobants S; Mortelmans L; Schöffski P; Van Oosterom A
Anticancer Res; 2006; 26(2A):1247-52. PubMed ID: 16619531
[TBL] [Abstract][Full Text] [Related]
57. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Chi P; Chen Y; Zhang L; Guo X; Wongvipat J; Shamu T; Fletcher JA; Dewell S; Maki RG; Zheng D; Antonescu CR; Allis CD; Sawyers CL
Nature; 2010 Oct; 467(7317):849-53. PubMed ID: 20927104
[TBL] [Abstract][Full Text] [Related]
58. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy.
Antonescu CR; Romeo S; Zhang L; Nafa K; Hornick JL; Nielsen GP; Mino-Kenudson M; Huang HY; Mosquera JM; Dei Tos PA; Fletcher CD
Am J Surg Pathol; 2013 Mar; 37(3):385-92. PubMed ID: 23348204
[TBL] [Abstract][Full Text] [Related]
59. In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice.
Ishikawa T; Nakai N; Liu NN; Shiba K; Isozaki K; Matsuda I; Ito T; Fujimoto J; Hatakeyama K; Kanda T; Hirota S
Lab Invest; 2009 Oct; 89(10):1161-8. PubMed ID: 19636292
[TBL] [Abstract][Full Text] [Related]
60. Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.
Pirson L; Baron F; Meuris N; Giet O; Castermans E; Greimers R; Di Stefano I; Gothot A; Beguin Y
Stem Cells; 2006 Jul; 24(7):1814-21. PubMed ID: 16614006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
